Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · Jun 7, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how a medication called empagliflozin affects oxidative stress in patients who have type 2 diabetes and have recently received a kidney transplant. Oxidative stress can lead to complications after transplantation, so the researchers want to see if adding empagliflozin to insulin therapy can help reduce this stress. The study involves comparing two groups of patients: one group will receive empagliflozin along with insulin, while the other group will get insulin only. Each group will have 20 participants, and they will be monitored for changes in certain markers related to oxidative stress over a 90-day period.

To participate in this trial, you need to be diagnosed with type 2 diabetes, have a specific level of blood sugar control (measured by HbA1c), and be in a stable condition after your kidney transplant. Unfortunately, if you have had a pancreas and kidney transplant or have a history of frequent urinary tract infections, you won’t be eligible. Participants can expect to undergo tests to measure oxidative stress and will play a role in potentially contributing to important findings that could help improve care for patients after kidney transplants. The results will be shared in a scientific journal, helping to inform future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with type 2 diabetes
• • HbA1c: 6.5-9.0%
• • post kidney transplant
• • stable graft function
• Exclusion Criteria:
• • pancreas and kidney transplant
• • history of recurrent urinary tract infection